Journal of Psychopharmacology
May 30, 2022
Chaitra Jairaj, James J Rucker
13 citations
Postpartum depression (PPD) involves a core sense of maternal disconnection from self, infant, and support system, and differs from major depressive disorder (MDD), especially regarding the mother-infant relationship. Current PPD treatments, borrowed from MDD, show low remission rates and emerging treatment resistance. This narrative review proposes that serotonergic psychedelics, particularly psilocybin, could treat PPD by fostering reconnection. Evidence from MDD trials indicates psilocybin is safe and shows encouraging efficacy, catalyzing reconnection. In PPD, this reconnection might improve mood and maternal sensitivity, enhancing maternal role gratification and the mother-infant relationship. Psychedelic-assisted therapy for PPD warrants further examination.
Psychedelic medicine (New Rochelle, N.Y.)
June 1, 2025
Sara Shoar, Alissa Bazinet, Chaitra Jairaj
2 citations
A narrative mini-review highlights a gap in understanding the safety of psychedelic use during critical stages of the female reproductive cycle, including menstruation, pregnancy, postpartum, breastfeeding, and menopause. Sex differences exist in users' subjective and physiological experiences of psychedelics. Interactions between psychedelics' mechanisms and female hormones suggest potential for addressing symptoms of menstruation, sexual dysfunction, chronic pelvic pain, menopause, and postpartum depression. Traditional indigenous use of psychedelics in healing rituals is noted. Risks during gestation and breastfeeding underscore the need for caution. Comprehensive research on women is lacking; public health messaging should promote risk reduction and culturally sensitive approaches.
Therapeutic Advances in Psychopharmacology
March 1, 2026
Guillaume Thuery, Frank Crossen, Daniel Mc Loone et al.
1 citation
About 15% of pregnant women experience postpartum depression, and many remain impaired despite available antidepressants. Serotonergic psychedelics may offer a viable therapeutic approach for postpartum depression, though the benefit-risk ratio is unclear. This review summarizes immune, endocrine, and neural pathways underlying postpartum depression and explores how psychedelics interact with these pathways in relation to maternal motivation, bonding, and caregiving. Special considerations for psychedelic therapy in the postpartum period are outlined. Further research, especially longitudinal trials with adaptations for the postpartum context, is needed to determine efficacy and safety.